-+ 0.00%
-+ 0.00%
-+ 0.00%
GlaxoSmithKline: It is expected to launch 22 phase III clinical trials in 2026, and 18 have been initiated so far.
Share
Listen to the news
GlaxoSmithKline: It is expected to launch 22 phase III clinical trials in 2026, and 18 have been initiated so far.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending